文献速递骨肌介入技术与安全USMRPETCT

局部区域治疗与免疫治疗时代的软组织肿瘤影像与介入

Imaging and intervention for soft tissue tumours in the era of locoregional therapies and immunotherapy.
PubMed 文献 · Clin Radiol · 2025-05-24

本临床放射学综述面向非专科横断面顾问放射科医生及对骨肌肿瘤学有特殊兴趣的初级放射科顾问/专科培训生,概述超声与MRI在软组织肉瘤和硬纤维瘤诊断、分期及疗效评估中的作用,讨论FDG PET/CT与MRI疗效评估及全身MRI的新兴作用,介绍RECIST 1.1、改良RECIST、PERCIST、iRECIST、iPERCIST及非灌注体积比等疗效指标,并探讨局部区域治疗(微波、冷冻、治疗性超声)作为英国指南背景下选定病例辅助治疗的潜在作用及高强度聚焦超声的远隔效应。

要点

  • 临床放射学在软组织肉瘤和硬纤维瘤的多学科团队中承担诊断、分期和疗效评估的关键角色,通常联合超声与MRI。
  • 介入放射学在复发性和寡转移性软组织肉瘤及硬纤维瘤治疗中的作用日益增加。
  • FDG PET/CT和MRI用于软组织肉瘤与硬纤维瘤疗效评估,全身MRI为新兴角色,并涉及RECIST 1.1、PERCIST、iRECIST等多种疗效指标。

核心结论

  • 临床放射学在多学科团队中对软组织肉瘤和硬纤维瘤的诊断、分期和疗效评估起关键作用,介入放射学在复发和寡转移性疾病中作用增加;局部区域治疗(微波、冷冻、治疗性超声)可作为英国指南背景下选定病例的辅助治疗,高强度聚焦超声等局部区域治疗有潜力系统性释放肉瘤肿瘤抗原以增强抗肿瘤免疫(远隔效应),免疫治疗已出现针对选定软组织肉瘤亚型的首批适应证。

研究设计与样本

  • 临床放射学综述,主要面向非专科横断面顾问放射科医生及对骨肌肿瘤学有特殊兴趣的初级放射科顾问/专科培训生,未报告系统检索范围与纳入文献数量。

诊断标准与关键数值

  • 疗效评估指标包括实体瘤疗效评价标准1.1(RECIST 1.1)、改良RECIST、实体瘤正电子发射断层扫描疗效标准(PERCIST)、免疫实体瘤疗效评价标准(iRECIST)、iPERCIST及非灌注体积比。
  • 局部区域治疗包括微波、冷冻治疗和治疗性超声为基础的治疗。

临床应用与阅片要点

  • 临床放射学在多学科团队中承担软组织肉瘤和硬纤维瘤的诊断、分期和疗效评估,通常联合超声与MRI。
  • 局部区域治疗(微波、冷冻、治疗性超声)可作为英国指南背景下选定病例的辅助治疗。
  • 高强度聚焦超声和其他局部区域治疗有潜力系统性释放肉瘤肿瘤抗原,可能增强抗肿瘤免疫(远隔效应)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

As part of a multidisciplinary team, clinical radiology plays key roles in the diagnosis, staging and treatment response assessment for soft tissue sarcoma (STS) and desmoid tumours (DTs), typically using a combination of ultrasound and magnetic resonance imaging (MRI) modalities. There is an increasing role for interventional radiology in the treatment of recurrent and oligometastatic disease in these tumour types. This clinical radiology review is aimed primarily at non-specialist cross-sectional consultant radiologists and more junior radiology consultants/specialist trainees with a special interest in musculoskeletal oncology. The existing role of F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) and MRI for assessment of treatment response in STS and DT, including the emerging role of whole-body MRI is outlined. Response metrics including Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1), modified RECIST, Positron Emission Tomography Response Criteria in Solid Tumours (PERCIST), immune Response Evaluation Criteria in Solid Tumors, iPERCIST and non-perfused volume ratio are also discussed in context. We introduce the potential role for locoregional therapies (LRTs), including microwave, cryotherapy and therapeutic ultrasound-based treatments as adjunctive treatments for selected cases within the current UK guidelines. We discuss the potential of high intensity focused ultrasound and other LRTs to release sarcoma tumour antigens systemically with the potential to enhance anti-tumour immunity (the 'abscopal' effect). With increasing indications and availability of locoregional therapies (LRTs) and the first indications of immunotherapy for selected subtypes of STS, potential future directions in functional imaging capability for STS and DT are also discussed.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Rehman S, McCarthy C, Chetan M, et al. Imaging and intervention for soft tissue tumours in the era of locoregional therapies and immunotherapy. Clin Radiol. 2025. PMID: 40533275. doi:10.1016/j.crad.2025.106969

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。